|
 |
 |
|
Ellipsis Biotherapeutics Corporation provides commercial genotyping services, including research capabilities for development of novel genetic tests and gene discovery. It was incorporated in Ontario, Canada, in 1997.
As part of its founding mission to investigate genetic susceptibility to inflammatory disease, Ellipsis established fully automated high throughput SNP analysis capabilities. Ellipsis has leveraged this core expertise in human disease research and genetic analysis to provide superior quality genotyping services to government, academic and industrial clients.
Ellipsis provides a wide range of SNP services using state-of-the-art technologies. With these platforms, Ellipsis can support customers throughout the entire progression of their SNP studies.
With the focused objective of providing high quality SNP genotyping to the marketplace and the commitment of dedicated resources, Ellipsis delivers quality and accurate results rapidly, translating to faster turn-around times and higher value results for our customers.
For further information about the company and our team, please choose one of
the links on the left side of your screen.
Fast. Accurate. Designed to suit your needs.
|
|
|
|
|
